Abstract
Genetic immunization with lentiviral vectors is under evaluation as a means for induction of sustained immune response. Lentiviral vectors showed reduced antivector immune responses and efficiently transduced post-mitotic cells in vivo, including antigen presenting cells, such as dendritic cells and macrophages, thus providing a significant benefit over other vector-based antigen delivery platforms. Several evidences indicate that a single immunization with lentiviral vectors induces strong and sustained effector and memory T-cell immune responses, as well as antibody production. New generation of lentiviral vectors with improved biosafety profile are also under development. In particular, integration defective lentiviral vectors have been generated and used as an efficient and safe delivery system for both gene therapy and immunization purposes. Taken together, these evidences support the ongoing development of lentiviral vector-based genetic immunization strategies for safe applications in the clinic.
Keywords: Lentiviral vector, integrase, immunization, vaccine
Current HIV Research
Title: Toward Integrase Defective Lentiviral Vectors for Genetic Immunization
Volume: 8 Issue: 4
Author(s): Donatella R.M. Negri, Zuleika Michelini and Andrea Cara
Affiliation:
Keywords: Lentiviral vector, integrase, immunization, vaccine
Abstract: Genetic immunization with lentiviral vectors is under evaluation as a means for induction of sustained immune response. Lentiviral vectors showed reduced antivector immune responses and efficiently transduced post-mitotic cells in vivo, including antigen presenting cells, such as dendritic cells and macrophages, thus providing a significant benefit over other vector-based antigen delivery platforms. Several evidences indicate that a single immunization with lentiviral vectors induces strong and sustained effector and memory T-cell immune responses, as well as antibody production. New generation of lentiviral vectors with improved biosafety profile are also under development. In particular, integration defective lentiviral vectors have been generated and used as an efficient and safe delivery system for both gene therapy and immunization purposes. Taken together, these evidences support the ongoing development of lentiviral vector-based genetic immunization strategies for safe applications in the clinic.
Export Options
About this article
Cite this article as:
R.M. Negri Donatella, Michelini Zuleika and Cara Andrea, Toward Integrase Defective Lentiviral Vectors for Genetic Immunization, Current HIV Research 2010; 8 (4) . https://dx.doi.org/10.2174/157016210791208622
DOI https://dx.doi.org/10.2174/157016210791208622 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neuroendocrine Tumors of the Lung: Hystological Classification, Diagnosis, Traditional and New Therapeutic Approaches
Current Medicinal Chemistry Current Advances in the Synthesis and Biological Evaluation of Pharmacologically Relevant 1,2,4,5-Tetrasubstituted-1H-Imidazole Derivatives
Current Organic Chemistry Development of New Fibrinolytic Agents
Current Pharmaceutical Design Targeting Synthetic Lethality in DNA Damage Repair Pathways as an Anti-Cancer Strategy
Current Drug Targets DNA Vaccines for Prostate Cancer
Current Cancer Therapy Reviews In Vitro and In Vivo Evaluation of [99mTc(CO)3]-Radiolabeled ErbB-2-Targeting Peptides for Breast Carcinoma Imaging
Current Radiopharmaceuticals Microarray Technologies for Intracellular Kinome Analysis
Current Medicinal Chemistry Foreword
Current Drug Delivery NOTCH Signaling as a Novel Cancer Therapeutic Target
Current Cancer Drug Targets Arsenic trioxide Alters the MicroRNA Expression Profile of U87 glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Spherical Self-Organizing Map Detects MYBL 1 As Candidate Gene for Triple-Negative Breast Cancer
Neuroscience and Biomedical Engineering (Discontinued) Extra-Hematopoietic Effects of Erythropoietin
Cardiovascular & Hematological Disorders-Drug Targets The Role of the ATP-Binding Cassette Transporter P-Glycoprotein in the Transport of β-Amyloid Across the Blood-Brain Barrier
Current Pharmaceutical Design Bioactive Principles and Potentiality of Hot Methanolic Extract of the Leaves from <i>Artemisia absinthium</i> L “<i>in vitro</i> Cytotoxicity Against Human MCF-7 Breast Cancer Cells, Antibacterial Study and Wound Healing Activity”
Current Pharmaceutical Biotechnology Antioxidants as a Potential Preventive and Therapeutic Strategy for Cadmium
Current Drug Targets Evaluation of the Anticancer Activities of the Plant Alkaloids Sanguinarine and Chelerythrine in Human Breast Adenocarcinoma Cells
Anti-Cancer Agents in Medicinal Chemistry Synthesis and Characterization of New Zinc Phthalocyanine - Dodecenyl Succinic Anhydride Benzoic Groups
Current Organic Synthesis Spinophilin: A New Tumor Suppressor at 17q21
Current Molecular Medicine From Multiple PAR1 Receptor/Protein Interactions to their Multiple Therapeutic Implications
Current Topics in Medicinal Chemistry Silymarin in the Prevention and Treatment of Liver Diseases and Primary Liver Cancer
Current Pharmaceutical Biotechnology